San Francisco, California-based Bone Health Technologies has exciting additions including $2.5 million in new funding and three new board members.
Osteoporosis Company Lands $2.5M Funding, Adds to BOD
2 min read Premium comments
Secondary#bonehealthtechnologies
This month, Bone Health Technologies announced the successful close of its $2.5 million oversubscribed funding round, led by Good Growth Capital. The press release named other investors including Astia Angels, Ambit Health Ventures, Portfolia Femtech Fund, IT-Farm Corporation, Golden Seeds, Berkeley Angel Network, the Band of Angels, and Reno Seed Fund. It also included several notable individual angel investors.
OTW discussed the funding with Bone Health Technologies CEO Laura Yecies. “This funding round, by allowing us to invest in a robust pivotal trial and infrastructure for a broad solution for bone health, is playing an important role in our journey to help the millions of patients with osteopenia and prevent osteoporosis.”
Bone Health Technologies is developing technology to enhance bone health. According to its website, over 54 million Americans have osteopenia (the precursor to osteoporosis) or osteoporosis. It is combating this problem with its current solution, the OsteoBoost. Per its website, the OsteoBoost is the “first vibration belt specifically designed for the prevention of osteoporosis.”
In addition to the funding round, Bone Health Technologies also announced the appointment of three board members: Karen Drexler, M.B.A.; Nancy Lynch, M.D., M.B.A.; and Sam Goldberger, M.D., M.B.A.
Drexler is a founding member of one of the investors, Astia Angels. She serves on several other notable boards including ResMed and Outset Medical, Inc. She brings both her commercial expertise as well as her chemical engineering education to the board.
Dr. Lynch is a board-certified, fellowship-trained orthopedic surgeon and a fellow of the American Academy of Orthopaedic Surgeons. She has over 25 years of orthopedics experience, encompassing all elements of the industry including medical and business. She is also the founder and principal of Advisorthopaedics Incorporated, an orthopedic innovation consultancy.
Dr. Goldberger has more than “28 years of surgical experience” and is an expert in both ophthalmology and cosmetic surgery. He is also a founding member and managing partner of another investor, Ambit Health Ventures. According to Dr. Goldberger’s LinkedIn profile, Ambit Health Ventures is a “boutique healthcare innovation venture capital firm.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.